Disease relevance of Eloxatin

• Oxaliplatin (Eloxatin) is the only platinum compound to show clinical activity in colorectal cancer [1].
• The relationship between the rhythm in tissue nonprotein sulphydryl groups (NPSH) and that in 1,2-diamine (trans-I)-cyclohexane oxalatoplatinum (1-OHP) toxicity was investigated in a total of 266 male B6D2F1 mice, using buthionine sulphoximine (BSO), an inhibitor of gamma-glutamylcysteine synthetase [2].

High impact information on Eloxatin

• Oxaliplatin (Eloxatin) plus irinotecan combination chemotherapy found effective in refractory metastatic insular thyroid carcinoma [3].
• Oxaliplatin (Eloxatin) is a third-generation platinum derivative with an in vitro and in vivo spectrum of activity distinct from that of cisplatin, especially in colon cancer cells [4].
• Postoperatively the patient underwent a palliative chemotherapy with eloxatin, FU, and leucovorin [5].
• In a National Surgical Adjuvant Breast and Bowel Project phase II trial in 54 patients with previously untreated advanced colorectal cancer, pemetrexed at 500 mg/m2 plus oxaliplatin (Eloxatin) at 120 mg/m2 every 21 days with folic acid/vitamin B12 supplementation resulted in an objective response of 23% [6].
• Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis [7].

Chemical compound and disease context of Eloxatin

• Oxaliplatin (Eloxatin; Sanofi, Gentilly, France), a third-generation platinum compound with a 1,2-diaminocyclohexane (DACH) carrier ligand, is a recently developed agent with activity in colorectal cancer (CRC) [8].
• Oxaliplatin (Eloxatin), a new platinum analog, has demonstrated high activity in the treatment of colorectal cancer, especially when combined with 5-FU and leucovorin [9].

Anatomical context of Eloxatin

• Given the promising activity of oxaliplatin (Eloxatin), 5-FU, and leucovorin, a trial is now in development to assess the efficacy of this combination when used together with hepatic artery infusion [10].

Associations of Eloxatin with other chemical compounds

• A recent European trial (MOSAIC) has documented significant improvement in 3-year disease-free survival when oxaliplatin (Eloxatin) was added to infusional 5-FU and leucovorin in the FOLFOX regimen [11].

References